IntelliCell inks licensing deal with pet company Paws

IntelliCell BioSciences (OTC:SVFC) said on Tuesday it has signed a licensing deal with pet services company Paws (OTC:PAWS), set to boost IntelliCell’s presence in the pet industry.
IntelliCell, through its proprietary technology, processes stromal vascular fraction stem cells, derived from people’s body fat.
Fat stem cells are cutting edge, with many practitioners and companies researching the use of them for anti-aging effects, as well as for the treatment of more serious conditions like arthritis, congestive heart failure, gum recession, and wound healing.
Since the middle of 2009 when the U.S. Food and Drug Administration published its laws on autologous stem cells, the field has expanded rapidly.
Numerous studies have also been conducted on animals for veterinary applications over the last few decades.
The collaboration between IntelliCell and Paws will make fat-derived stem cells available to the veterinary world for use in a full-spectrum of pet applications.
"Our deal with The PAWS Pet Company is a very exciting advancement for veterinary medicine. With their marketing skills in the animal world and our advanced technology we have a winning formula for treating animals with 'IntelliCells' which has a high concentration of stem cells," Steven Victor, CEO of IntelliCell, said in a statement.
PAWS CEO, Dan Wiesel, added: "We are excited to be working with IntelliCell to bring their regenerative medicine treatment to the pet marketplace.
"Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets."
IntelliCell’s adipose stem cell processing technique takes about 30 minutes and the stem cells can be returned to the veterinarian in the same day.
The New York-based company has processing centers in New York City, Philadelphia, Dallas, and New Orleans.